Quick Links

The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts.

Authors: Guohu Li|||Peter Whittaker|||Mu Yao|||Robert A Kloner|||Karin Przyklenk

Journal: Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology

Publication Type: Journal Article

Date: 2002

DOI: 10.1016/s1054-8807(02)00102-3

ID: 12031768

Affiliations:

Affiliations

    Heart Institute/Research, Good Samaritan Hospital and Section of Cardiology, Department of Medicine, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA.||||||||||||

Abstract

Emerging evidence suggests that gap junction-mediated intercellular transmission of ions, metabolites and/or second messengers may serve as important determinants of myocyte viability. Our aim was to determine, using isolated buffer-perfused mouse hearts, whether the cardioprotection achieved with ischemic preconditioning (PC) is due in part to: (i) disruption of cell-cell coupling (manifest as a loss in the primary gap junction protein, connexin 43 [Cx43]) and resultant impaired transmission of a 'death' messenger, or conversely, (ii) transfer of a humoral 'survival' factor via existing gap junctions.


Chemical List

    Connexin 43|||Heptanol